Blockchain Registration Transaction Record

NeuroOne's New System Ends 'Suicide Disease' Pain in 12 Patients

NeuroOne's FDA-cleared OneRF system successfully treats trigeminal neuralgia pain in 12 patients using a multi-contact probe that eliminates need for repositioning during surgery.

This development matters because trigeminal neuralgia affects approximately 150,000 people in the U.S., causing debilitating facial pain that disrupts daily life and has earned the grim nickname 'suicide disease' due to its severity. Current treatments often involve invasive surgeries with multiple anesthesia cycles, increasing patient discomfort and procedural time. NeuroOne's technology offers a more efficient, less traumatic alternative by enabling precise treatment in a single procedure, potentially reducing hospital stays, lowering healthcare costs, and significantly improving quality of life for sufferers. It represents a meaningful advance in neuromodulation, aligning with broader trends toward minimally invasive, patient-centric medical solutions.